<DOC>
	<DOCNO>NCT02598063</DOCNO>
	<brief_summary>This study evaluate efficacy safety peginterferon alfa-2a ADV , participants lamivudine-resistant HBeAg-positive chronic hepatitis B . Participants randomize receive either peginterferon alfa-2a 48 week combination oral lamivudine first 12 week , ADV 72 week combination oral lamivudine first 12 week . The anticipated time study treatment 72 week , target sample size 255 individual .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Peginterferon Alfa-2a ( Pegasys ) Adeforvir Dipivoxil ( ADV ) Participants With Lamivudine-Resistant Hepatitis B e Antigen ( HBeAg ) -Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adult participant 1865 year age Hepatitis B surface antigen ( HBsAg ) positive , HBeAgpositive , antiHBsnegative great equal ( &gt; = ) 6 month Receiving lamivudine currently , &gt; =6 month hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) decrease &gt; =2 log lamivudine treatment &gt; =1 occasion Absence cirrhosis confirm liver biopsy previous 6 month Other drug activity HBV within prior 6 month , except lamivudine Antiviral , antineoplastic , immunomodulatory therapy less equal ( &lt; = ) 6 month study Active infection hepatitis A , C , D virus , human immunodeficiency virus Decompensated liver disease Medical condition associate another chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>